Cell and Gene Manufacturing and Logistics

  1. Addressing Plasmid DNA Challenges In Large-Scale AAV And Lentivirus Manufacturing Using dbDNA 9/21/2026

    Plasmid DNA supply and regulatory concerns constrain large-scale viral vector manufacturing. Here, we examine whether enzymatically generated dbDNA can deliver comparable rAAV and rLV production outcomes.

  2. How Single-Use Filtration Optimizes Cell Therapy And Fluid Management Workflows 9/18/2026

    Explore how filter size, membrane material, flow performance, and hold-up volume influence sterility, aggregate control, product recovery, and process efficiency across cell therapy workflows.

  3. Cell Therapy QC Automation: Getting Integration Right 9/17/2026

    Scaling cell therapy requires a new approach to quality control. Learn how integrated systems, improved data flow, advanced analytics, and thoughtful automation can support faster decisions.

  4. The Phase 2 Manufacturing Wall: The CMC Risk Hiding In Plain Sight 9/17/2026

    Hidden gaps in process maturity and organizational alignment can derail development. Discover how to identify risks early and improve readiness for key milestones.

  5. In Case You Missed Them: Recapping The FDA's Recent Guidances For Cell And Gene Therapies 9/17/2026

    I review 10 of the FDA’s guidances spanning the last 12 months, all of which aid cell and gene therapy companies to assure safety and efficacy of these medicines.

  6. Characterizing Gene-Edited T Cells Using High-Throughput Expression 9/16/2026

    Gene expression profiling reveals whether engineered T cells display intended molecular changes while helping identify unwanted effects. See how a standardized workflow can improve consistency.

  7. New USP Guidelines, Standards Address Lentivirus Characterization 9/16/2026

    The United States Pharmacopeia is rolling out new standards and tools to help manufacturers characterize fragile, complex lentiviral vectors.

  8. Transforming Gene Therapy With A Scalable Platform Solution 9/15/2026

    Discover how a platform approach to AAV manufacturing can reduce development time and cost, as well as how optimized processes enable reliable production and scalable implementation in bioreactors.

  9. Viral Vector Services 9/15/2026

    Fast-track your Gene Therapies from cutting-edge process development to commercial success with advanced viral vector manufacturing solutions!

  10. Driving Productivity Across The Antibody Manufacturing Workflow 9/14/2026

    Learn how integrated upstream and downstream strategies can reduce harvest bottlenecks, improve purification efficiency, and support scalable therapeutic antibody manufacturing.